The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | TP53-mutant AML linked to poorer outcomes with decitabine plus venetoclax
Kunhwa Kim, MD, MPH, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the results of a post-hoc analysis of a Phase II trial (NCT03404193) investigating the outcomes of patients with TP53-mutant acute myeloid leukemia (AML) when treated with venetoclax plus decitabine in the frontline setting. The study found that TP53-mutant AML patients had a complete response (CR) rate of 35% to decitabine plus venetoclax therapy and a median overall survival (OS) of 5.2 months, compared to a CR of 57% and a median OS of 19.4 months in wild-type TP53 patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
